Mouse monoclonal antibody raised against partial recombinant MLL.
Immunogen:
Recombinant protein corresponding to amino acids 3751-3968 of human MLL.
Host:
Mouse
Reactivity:
Human
Form:
Liquid
Isotype:
IgG1
Recommend Usage:
ELISA (1:10000) Western Blot (1:500-1:2000) Immunohistochemistry (1:200-1:1000) The optimal working dilution should be determined by the end user.
Storage Buffer:
In ascites (0.03% sodium azide)
Storage Instruction:
Store at 4°C. For long term storage store at -20°C. Aliquot to avoid repeated freezing and thawing.
Note:
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Applications
Western Blot
Western blot analysis using MLL monoclonal antibody, clone 10F8D7 (Cat # MAB10562) against truncated MLL recombinant protein (1) and truncated GFP-MLL(aa 3714-3969) transfected COS-7 cell lysate (2).
Immunohistochemical analysis of paraffin-embedded human lung cancer (A) and esophagus cancer (B), showing nuclear weak staining with DAB staining using MLL monoclonal antibody, clone 10F8D7 (Cat # MAB10562).
The MLL gene encodes a DNA-binding protein that methylates histone H3 (see MIM 601128) lys4 (H3K4) and positively regulates expression of target genes, including multiple HOX genes (see MIM 142980). MLL is a frequent target for recurrent translocations in acute leukemias that may be characterized as acute myeloid leukemia (AML; MIM 601626), acute lymphoblastic leukemia (ALL), or mixed lineage (biphenotypic) leukemia (MLL). Leukemias with translocations involving MLL possess unique clinical and biologic characteristics and are often associated with poor prognosis. MLL rearrangements are found in more than 70% of infant leukemias, whether the immunophenotype is more consistent with ALL or AML6, but are less frequent in leukemias from older children. MLL translocations are also found in approximately 10% of AMLs in adults, as well as in therapy-related leukemias, most often characterized as AML, that develop in patients previously treated with topoisomerase II inhibitors for other malignancies. More than 50 different MLL fusion partners have been identified. Leukemogenic MLL translocations encode MLL fusion proteins that have lost H3K4 methyltransferase activity. A key feature of MLL fusion proteins is their ability to efficiently transform hematopoietic cells into leukemia stem cells (Krivtsov and Armstrong, 2007 [PubMed 17957188]).[supplied by OMIM